Evidence map›Paper›PMID 34168281›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2021

Myxoid pleomorphic liposarcoma-a clinicopathologic, immunohistochemical, molecular genetic and epigenetic study of 12 cases, suggesting a possible relationship with conventional pleomorphic liposarcoma.

David Creytens, Andrew L Folpe, Christian Koelsche, Thomas Mentzel, Liesbeth Ferdinande, Joost M van Gorp, Malaïka Van der Linden, Lennart Raman, Björn Menten, Karen Fritchie and 3 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 56 citations in OpenAlex.

  1. Review
  2. Liposarcoma: State of the Art-A Scoping Review.Medical sciences (Basel, Switzerland) · 2026
    Article
  3. Review
  4. Review
  5. Nuclear medicine and molecular imaging · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Diagnosis and Treatment of Myxoid Liposarcoma.Current treatment options in oncology · 2024
    Review
  10. Review
  11. Myxoid pleomorphic liposarcoma.Histology and histopathology · 2024
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Mandibular Myxoid Liposarcoma: a Case Study.Indian journal of surgical oncology · 2024
    Review
  17. Article
  18. Review
  19. Article
  20. Myxoid liposarcoma with nuclear pleomorphism: a clinicopathological and molecular study.Virchows Archiv : an international journal of pathology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 4 countries.

David CreytensDepartment of Pathology, Ghent University Hospital, Ghent, Belgium. david.creytens@uzgent.be.
Andrew L FolpeDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Christian KoelscheDepartment of General Pathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.ORCID 0000-0001-8763-8864
Thomas MentzelDermatopathology Bodensee, Friedrichshafen, Germany.
Liesbeth FerdinandeDepartment of Pathology, Ghent University Hospital, Ghent, Belgium.
Joost M van GorpDepartment of Pathology, St Antonius Hospital, Nieuwegein, The Netherlands.
Malaïka Van der LindenDepartment of Pathology, Ghent University Hospital, Ghent, Belgium.
Lennart RamanDepartment of Pathology, Ghent University Hospital, Ghent, Belgium.ORCID 0000-0002-3840-5930
Björn MentenCenter for Medical Genetics, Ghent University, Ghent, Belgium.
Karen FritchieDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-2336-3691
Andreas von DeimlingDepartment of General Pathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.ORCID 0000-0002-5863-540X
Jo Van Dorpe *Department of Pathology, Ghent University Hospital, Ghent, Belgium.ORCID 0000-0001-8175-2930
Uta Flucke *Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
Ghent University Hospital · BEHeidelberg University · DEMayo Clinic in Arizona · USDermatopathologie Friedrichshafen · DERadboud University Nijmegen · NLSt. Antonius Ziekenhuis · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myxoid pleomorphic liposarcoma is a recently defined subtype of liposarcoma, which preferentially involves the mediastinum of young patients and shows mixed histological features of conventional myxoid liposarcoma and pleomorphic liposarcoma. While myxoid pleomorphic liposarcoma is known to lack the EWSR1/FUS-DDIT3 fusions characteristic of the former, additional genetic data are limited. To further understand this tumor type, we extensively examined a series of myxoid pleomorphic liposarcomas by fluorescence in situ hybridization (FISH), shallow whole genome sequencing (sWGS) and genome-wide DNA methylation profiling. The 12 tumors occurred in 6 females and 6 males, ranging from 17 to 58 years of age (mean 33 years, median 35 years), and were located in the mediastinum (n = 5), back, neck, cheek and leg, including thigh. Histologically, all cases consisted of relatively, bland, abundantly myxoid areas with a prominent capillary vasculature, admixed with much more cellular and less myxoid foci containing markedly pleomorphic spindled cells, numerous pleomorphic lipoblasts and elevated mitotic activity. Using sWGS, myxoid pleomorphic liposarcomas were found to have complex chromosomal alterations, including recurrent large chromosomal gains involving chromosomes 1, 6-8, 18-21 and losses involving chromosomes 13, 16 and 17. Losses in chromosome 13, in particular loss in 13q14 (including RB1, RCTB2, DLEU1, and ITM2B genes), were observed in 4 out of 8 cases analyzed. Additional FISH analyses confirmed the presence of a monoallelic RB1 deletion in 8/12 cases. Moreover, nuclear Rb expression was deficient in all studied cases. None showed DDIT3 gene rearrangement or MDM2 gene amplification. Using genome-wide DNA methylation profiling, myxoid pleomorphic liposarcomas and conventional pleomorphic liposarcomas formed a common methylation cluster, which segregated from conventional myxoid liposarcomas. While the morphologic, genetic and epigenetic characteristics of myxoid pleomorphic liposarcoma suggest a link with conventional pleomorphic liposarcoma, its distinctive clinical features support continued separate classification for the time being.

Indexed as

AdolescentAdultDNA MethylationDNA, NeoplasmEpigenomicsFemaleHead and Neck NeoplasmsHumansImmunohistochemistryIn Situ Hybridization, FluorescenceLiposarcomaLiposarcoma, MyxoidMaleMediastinal NeoplasmsMiddle AgedMolecular BiologyDNA, NeoplasmNeoplasm Proteins

Identifiers

PMID34168281
OpenAlexW3175724063

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.